CytoArm CO., LTD.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
CytoArm’s flagship technology is its Armed-T™ cell therapy, which uses a non-viral manufacturing process to produce tumor-specific T cells with over 90% purity in around 10 days. The platform is highly adaptable, with the potential to develop treatments f
Founded Year
2020
Unified Business No.
83469938
Status
Active
Number of Employees
0
Total Paid-in
Capital
36,700,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
CytoArm Co., Ltd. is a Taiwan-based biotech company focused on next-generation T cell therapies. Leveraging its proprietary Armed-T™ platform, CytoArm equips T cells with bi-functional antibodies (BsAb) to enable precise tumor targeting, all without using viral-based gene modification, thereby offering a safer and more efficient immunotherapy approach.
